ArticleJournal of the American Heart Association2025
Comparative Mortality in Heart Failure on Guideline-Directed Medical Therapy Versus Malignant Cancer: A Report From a Global Federated Research Network.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network.ESC heart failure · 2026 · on this mapObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGuideline-directed medical therapy (GDMT), including angiotensin receptor-neprilysin inhibitor, angiotensin-converting enzyme inhibitors, beta blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors, has significantly improved outcomes in patients with heart failure with reduced ejection fraction (HFrEF). We examined whether modern GDMT alters the historically observed parity in mortality between HF and cancer.
methodsFrom the TriNetX Global Collaborative Research Network (2015-2024), we identified 32 125 patients with HFrEF on GDMT (angiotensin receptor-neprilysin inhibitor or angiotensin-converting enzyme inhibitors, mineralocorticoid receptor antagonists, beta blockers, and sodium-glucose cotransporter-2 inhibitors), 403 389 not on full GDMT (not receiving all 4 drugs concurrently), and 2 481 106 with malignant cancers. All-cause mortality was compared between HFrEF and cancer overall and across the most common cancers in men (prostate, colorectal, lung) and women (breast, lung, colorectal) using propensity score matching.
resultsPatients with HFrEF on GDMT with angiotensin receptor-neprilysin inhibitors had significantly better survival than patients with cancer (hazard ratio [HR], 0.44 [95% CI, 0.41-0.47];
conclusionsIn this large real-world analysis, patients with HFrEF on GDMT showed better survival than those with cancer overall and across most sex-specific cancers. Patients not on GDMT experienced worse outcomes, emphasizing the need to optimize treatment in HFrEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.